meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced (laHNSCC)
laHNSCC - (neo)adjuvant (NA)
laHNSCC - 1st line (L1)
1
laHNSCC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
versus all
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
avelumab based treatment
avelumab alone
laHNSCC - (neo)adjuvant (NA)
laHNSCC - 1st line (L1)
1
laHNSCC - 2nd line (L2)
Comparator:
vs placebo;
Risk of bias:
low;
some concerns;
high;
NA;